Physician profile
David Smith
NPI 1548612807
$1,839.20
in general payments reported to CMS, 2019-2025
13 companies · $821 in 2025
The $821 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.00 · 2022: $280 · 2023: $261 · 2024: $421 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348 · Education: $135 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.32 |
| Education | $135.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $579.81 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $337.60 | 2022-2024 | |
| Lilly USA, LLC | $196.67 | 2021-2025 | Mounjaro, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.86 | 2025 | Caplyta |
| Novo Nordisk INC | $134.02 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $97.50 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $94.62 | 2024-2025 | Auvelity, Symbravo |
| Astellas Pharma US INC | $90.00 | 2024 | |
| Exact Sciences Corporation | $56.81 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $37.73 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.05 | 2024 | Jardiance |
| Becton, Dickinson and Company | $20.00 | 2025 | Powerglide |
| Beone Medicines USA, INC. | $17.53 | 2025 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.